Search research articles
Contact Us
Filters
Showing results (11-20 of 41) with videos related to
Page
of 5
Sort By:
NPJ Systems Biology and Applications
|
March 6, 2026
Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effects
Youfang Cao, Brian A Willis, Kanta Horie, et al.
Molecular Neurodegeneration
|
April 20, 2012
Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling
Jacob M Basak, Jungsu Kim, Yuriy Pyatkivskyy, et al.
Molecular Neurodegeneration
|
June 7, 2014
Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics
Kristin R Wildsmith, Stephen P Schauer, Ashley M Smith, et al.
Alzheimer'S Research & Therapy
|
December 2, 2021
Baseline [<sup>18</sup>F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease
Edmond Teng, Paul T Manser, Sandra Sanabria Bohorquez, et al.
Molecular Neurodegeneration
|
February 6, 2026
Targeting tau in Alzheimer's Disease: rationale, approach and challenges
Aram Aslanyan, Martha S Foiani, Tatiana A Giovannucci, et al.
Alzheimer Disease and Associated Disorders
|
July 17, 2025
An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects
Sumit Rawal, Kristin R Wildsmith, Jagadeesh Aluri, et al.
Journal of Alzheimer'S Disease : JAD
|
November 22, 2021
Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer's Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated
Nicolas R Barthélemy, Balazs Toth, Paul T Manser, et al.
Neurobiology of Aging
|
July 8, 2019
Cross-sectional associations between [<sup>18</sup>F]GTP1 tau PET and cognition in Alzheimer's disease
Edmond Teng, Michael Ward, Paul T Manser, et al.
Frontiers in Neuroimaging
|
April 12, 2024
Evaluation of partial volume correction and analysis of longitudinal [<sup>18</sup>F]GTP1 tau PET imaging in Alzheimer's disease using linear mixed-effects models
Sandra M Sanabria Bohórquez, Suzanne Baker, Paul T Manser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Kristin R Wildsmith, Arnaud Charil, Tammie L S Benzinger, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 41) with videos related to
Sort By:
Page
of 5
NPJ Systems Biology and Applications
|
March 6, 2026
Neuro-Dynamic Quantitative Systems Pharmacology (QSP) model describing Alzheimer's disease pathophysiology and treatment effects
Youfang Cao, Brian A Willis, Kanta Horie, et al.
Molecular Neurodegeneration
|
April 20, 2012
Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling
Jacob M Basak, Jungsu Kim, Yuriy Pyatkivskyy, et al.
Molecular Neurodegeneration
|
June 7, 2014
Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics
Kristin R Wildsmith, Stephen P Schauer, Ashley M Smith, et al.
Alzheimer'S Research & Therapy
|
December 2, 2021
Baseline [<sup>18</sup>F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease
Edmond Teng, Paul T Manser, Sandra Sanabria Bohorquez, et al.
Molecular Neurodegeneration
|
February 6, 2026
Targeting tau in Alzheimer's Disease: rationale, approach and challenges
Aram Aslanyan, Martha S Foiani, Tatiana A Giovannucci, et al.
Alzheimer Disease and Associated Disorders
|
July 17, 2025
An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects
Sumit Rawal, Kristin R Wildsmith, Jagadeesh Aluri, et al.
Journal of Alzheimer'S Disease : JAD
|
November 22, 2021
Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer's Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated
Nicolas R Barthélemy, Balazs Toth, Paul T Manser, et al.
Neurobiology of Aging
|
July 8, 2019
Cross-sectional associations between [<sup>18</sup>F]GTP1 tau PET and cognition in Alzheimer's disease
Edmond Teng, Michael Ward, Paul T Manser, et al.
Frontiers in Neuroimaging
|
April 12, 2024
Evaluation of partial volume correction and analysis of longitudinal [<sup>18</sup>F]GTP1 tau PET imaging in Alzheimer's disease using linear mixed-effects models
Sandra M Sanabria Bohórquez, Suzanne Baker, Paul T Manser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Kristin R Wildsmith, Arnaud Charil, Tammie L S Benzinger, et al.
Page
of 5